Kim Hørslev-Petersen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5017359/publications.pdf

Version: 2024-02-01

158 papers 5,431 citations

71102 41 h-index 98798 67 g-index

160 all docs

160 docs citations

160 times ranked 5515 citing authors

#	Article	IF	CITATIONS
1	CXCL13 predicts long-term radiographic status in early rheumatoid arthritis. Rheumatology, 2022, 61, 2590-2595.	1.9	5
2	Increased synovial galectin-3 induce inflammatory fibroblast activation and osteoclastogenesis in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2022, , 1-9.	1.1	7
3	The effect of foot orthoses on gait biomechanics and pain among people with rheumatoid arthritis: A quasi-experimental study. Gait and Posture, 2022, 95, 121-128.	1.4	2
4	Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. Rheumatology, 2021, 60, 380-391.	1.9	6
5	Different types of foot orthoses effect on gait mechanics in patients with rheumatoid arthritis. Journal of Biomechanics, 2021, , 110496.	2.1	7
6	Foot and Ankle Problems in Patients With Rheumatoid Arthritis in 2019: Still an Important Issue. ACR Open Rheumatology, 2021, 3, 396-402.	2.1	12
7	Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial. Rheumatology International, 2021, 41, 543-549.	3.0	4
8	Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
9	Flares in rheumatoid arthritis: do patient-reported swollen and tender joints match clinical and ultrasonography findings?. Rheumatology, 2020, 59, 129-136.	1.9	18
10	Programmed death ligand 2 $\hat{a}\in$ A link between inflammation and bone loss in rheumatoid arthritis. Journal of Translational Autoimmunity, 2020, 3, 100028.	4.0	10
11	Pain and Self-reported Swollen Joints Are Main Drivers of Patient-reported Flares in Rheumatoid Arthritis: Results from a 12-month Observational Study. Journal of Rheumatology, 2020, 47, 1305-1313.	2.0	12
12	Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ, The, 2020, 371, m4328.	6.0	50
13	Does socioeconomic status make a difference? A register-based study on the extent to which cardiovascular screening in patients with inflammatory arthritis leads to recommended follow-up in general practice. RMD Open, 2020, 6, e000940.	3.8	2
14	Serial magnetic resonance imaging and ultrasound examinations demonstrate differential inflammatory lesion patterns in soft tissue and bone upon patient-reported flares in rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 19.	3.5	8
15	Impact of season on the association between vitamin D levels at diagnosis and one-year remission in early Rheumatoid Arthritis. Scientific Reports, 2020, 10, 7371.	3.3	8
16	ABO194â€VITAMIN D TRAJECTORIES IN EARLY DIAGNOSED, AGGRESSIVELY TREATED RHEUMATOID ARTHRITIS PATIENTS: A 10 YEAR LONGITUDINAL COHORT STUDY BASED ON THE DANISH CIMESTRA TRIAL. Annals of the Rheumatic Diseases, 2020, 79, 1397-1397.	0.9	0
17	Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 yearsâ \in [™] functional and radiographic outcome in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2019, 48, 1-8.	1.1	19
18	Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. Scandinavian Journal of Rheumatology, 2019, 48, 9-16.	1.1	18

#	Article	IF	CITATIONS
19	Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2019, 321, 461.	7.4	70
20	A parametric study of effect of experimental tibialis posterior muscle pain on joint loading and muscle forcesâ€"Implications for patients with rheumatoid arthritis?. Gait and Posture, 2019, 72, 102-108.	1.4	12
21	Tibialis posterior muscle pain effects on hip, knee and ankle gait mechanics. Human Movement Science, 2019, 66, 98-108.	1.4	10
22	Validity and Responsiveness of Combined Inflammation and Combined Joint Damage Scores Based on the OMERACT Rheumatoid Arthritis MRI Scoring System (RAMRIS). Journal of Rheumatology, 2019, 46, 1222-1227.	2.0	8
23	Interactions between women with rheumatoid arthritis and nurses during outpatient consultations: A qualitative study. Musculoskeletal Care, 2019, 17, 363-371.	1.4	1
24	†Isn't biological treatment something healthy?' Lay people's perceptions of medical terms. Scandina Journal of Rheumatology, 2019, 48, 253-255.	avjan 1.1	0
25	Juggling identities of rheumatoid arthritis, motherhood and paid work $\hat{a} \in \mathbb{C}$ a grounded theory study. Disability and Rehabilitation, 2019, 41, 1536-1544.	1.8	15
26	Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials. Scandinavian Journal of Rheumatology, 2018, 47, 259-269.	1.1	10
27	Impact of patient-reported flares on radiographic progression and functional impairment in patients with rheumatoid arthritis: a cohort study based on the AMBRA trial. Scandinavian Journal of Rheumatology, 2018, 47, 87-94.	1.1	10
28	Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial. Journal of Rheumatology, 2018, 45, 53-61.	2.0	35
29	The Dâ€vitamin metabolite 1,25(<scp>OH</scp>) ₂ D in serum is associated with disease activity and Antiâ€Citrullinated Protein Antibodies in active and treatment naÃve, early Rheumatoid Arthritis Patients. Scandinavian Journal of Immunology, 2018, 88, e12704.	2.7	14
30	Mortality and its predictors in patients with rheumatoid arthritis: a Danish population-based inception cohort study. Scandinavian Journal of Rheumatology, 2018, 47, 371-377.	1.1	13
31	Association between baseline vitamin D metabolite levels and long-term cardiovascular events in patients with rheumatoid arthritis from the CIMESTRA trial: protocol for a cohort study with patient-record evaluated outcomes. BMJ Open, 2017, 7, e014816.	1.9	4
32	Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients. Scandinavian Journal of Rheumatology, 2017, 46, 441-445.	1.1	6
33	Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. Trials, 2017, 18, 161.	1.6	19
34	Patient-specific foot orthotics improves postural control of rheumatoid arthritis patients: a pilot study. Footwear Science, 2017, 9, S17-S18.	2.1	1
35	Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 385-389.	1.2	11
36	Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials. Annals of the Rheumatic Diseases, 2017, 76, 1707-1715.	0.9	26

#	Article	IF	CITATIONS
37	Expression of soluble CD83 in plasma from early-stage rheumatoid arthritis patients is not modified by anti-TNF- \hat{l} ± therapy. Cytokine, 2017, 96, 1-7.	3.2	22
38	Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumabâ \in "a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clinical Rheumatology, 2017, 36, 781-789.	2.2	15
39	Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets. Arthritis Research and Therapy, 2017, 19, 80.	3.5	16
40	Construction of meaningful identities in the context of rheumatoid arthritis, motherhood and paid work: A metaâ€ethnography. Journal of Clinical Nursing, 2017, 26, 4117-4128.	3.0	11
41	Limited Reliability of Radiographic Assessment of Sacroiliac Joints in Patients with Suspected Early Spondyloarthritis. Journal of Rheumatology, 2017, 44, 70-77.	2.0	48
42	Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA). Scandinavian Journal of Rheumatology, 2017, 46, 335-345.	1,1	7
43	No diagnostic utility of antibody patterns against <i>Klebsiella pneumoniae</i> capsular serotypes in patients with axial spondyloarthritis vs. patients with non-specific low back pain: a cross-sectional study. Scandinavian Journal of Rheumatology, 2017, 46, 296-302.	1.1	8
44	Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study. Rheumatology International, 2017, 37, 113-120.	3.0	14
45	THU0601â€Cardiovascular screening among patients with inflammatory arthritis: to what extent do patients follow recommendations?., 2017,,.		0
46	Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response. PLoS ONE, 2016, 11, e0148486.	2.5	12
47	Associations Between Spondyloarthritis Features and Magnetic Resonance Imaging Findings: A Crossâ€Sectional Analysis of 1,020 Patients With Persistent Low Back Pain. Arthritis and Rheumatology, 2016, 68, 892-900.	5.6	71
48	A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis. Rheumatology, 2016, 55, 1871-1879.	1.9	17
49	Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial. BMJ Open, 2016, 6, e009134.	1.9	11
50	FRIO535â€Hand Bone Loss in Early Rheumatoid Arthritis Is Independent of Adalimumab Treatment. A Substudy of The Optimized Treatment Algorithm in Early RA (Opera) Trial. Annals of the Rheumatic Diseases, 2016, 75, 633.1-633.	0.9	0
51	AB0036â€Soluble CD83 Plasma Levels Are Associated with Disease Activity and Course of Disease in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 909.1-909.	0.9	O
52	The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression. Arthritis Research and Therapy, 2016, 18, 61.	3.5	26
53	The discriminative value of inflammatory back pain in patients with persistent low back pain. Scandinavian Journal of Rheumatology, 2016, 45, 321-328.	1.1	17
54	Diagnostic Delay in Rheumatoid Arthritis: A Qualitative Study of Symptom Interpretation Before the First Visit to the Doctor. Musculoskeletal Care, 2016, 14, 26-36.	1.4	19

#	Article	IF	Citations
55	Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci. Immunologic Research, 2016, 64, 55-63.	2.9	37
56	Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA). Annals of the Rheumatic Diseases, 2016, 75, 1645-1653.	0.9	40
57	Prevalence of degenerative and spondyloarthritis-related magnetic resonance imaging findings in the spine and sacroiliac joints in patients with persistent low back pain. European Radiology, 2016, 26, 1191-1203.	4.5	80
58	Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. Pharmacogenomics Journal, 2016, 16, 141-146.	2.0	58
59	Using an electronic platform interactively to improve treatment outcome in patients with rheumatoid arthritis: new developments from the DANBIO registry. Clinical and Experimental Rheumatology, 2016, 34, S75-S78.	0.8	8
60	OP0073â€Polymorphisms in the FCN1 Gene Coding for M-Ficolin are Associated with Disease Activity, Radiographic Damage and are the Strongest Predictors of DAS28 Remission in 180 DMARD Naive Early Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases, 2015, 74, 96.1-96.	0.9	0
61	Shared care or nurse consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis (RA) outpatients with stable low disease-activity RA: cost-effectiveness based on a 2-year randomized trial. Scandinavian Journal of Rheumatology, 2015, 44, 13-21.	1.1	34
62	Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial. Trials, 2015, 16, 178.	1.6	11
63	A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Annals of the Rheumatic Diseases, 2015, 74, 867-875.	0.9	49
64	Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2015, 44, 8-12.	1.1	22
65	Interleukin-23 in early disease development in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2015, 44, 438-442.	1.1	12
66	Withinâ€day variation and influence of physical exercise on circulating Galectinâ€3 in patients with rheumatoid arthritis and healthy individuals. Scandinavian Journal of Immunology, 2015, 82, 70-75.	2.7	14
67	Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs. Clinical and Experimental Rheumatology, 2015, 33, 498-502.	0.8	15
68	Which patients improve the most after arthritis rehabilitation? A study of predictors in patients with inflammatory arthritis in Northern Europe, the STAR-ETIC collaboration. Journal of Rehabilitation Medicine, 2014, 46, 250-257.	1.1	10
69	CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'. Arthritis Research and Therapy, 2014, 16, 434.	3.5	61
70	Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, 474.	3.5	28
71	CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients. Arthritis Research and Therapy, 2014, 16, 475.	3.5	12
72	Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. Annals of the Rheumatic Diseases, 2014, 73, 1123-1129.	0.9	26

#	Article	IF	CITATIONS
73	Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Annals of the Rheumatic Diseases. 2014. 73, 654-661.	0.9	108
74	Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2014, 43, 101-108.	1.1	79
75	Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression. Scandinavian Journal of Rheumatology, 2014, 43, 91-100.	1.1	19
76	Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity. Journal of Rheumatology, 2014, 41, 398-406.	2.0	71
77	Differentiation between early rheumatoid arthritis patients and healthy persons by conventional and dynamic contrast-enhanced magnetic resonance imaging. Scandinavian Journal of Rheumatology, 2014, 43, 109-118.	1.1	18
78	Low-field magnetic resonance imaging or combined ultrasonography and anti-cyclic citrullinated peptide antibody improve correct classification of individuals as established rheumatoid arthritis: results of a population-based, cross-sectional study. BMC Musculoskeletal Disorders, 2014, 15, 268.	1.9	5
79	Shared care or nursing consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis outpatients with low disease activityâ€"patient outcomes from a 2-year, randomised controlled trial. Annals of the Rheumatic Diseases, 2014, 73, 357-364.	0.9	78
80	THU0436â€Screening for Cardiovascular Risk According to Eular 2010 Recommendations in Outpatients with Psoriasis Arthritis or Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 333.2-333.	0.9	0
81	Reliability and responsiveness of dynamic contrast-enhanced magnetic resonance imaging in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2013, 42, 115-122.	1.1	37
82	Brief Report: Mâ€Ficolin Levels Reflect Disease Activity and Predict Remission in Early Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 3045-3050.	6.7	22
83	Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Annals of the Rheumatic Diseases, 2013, 72, 1771-1776.	0.9	58
84	ABO316â€Patient's global assessment of general health by vas at baseline predicts ACR/EULAR remission after 3, 6 and 12 month's of efficient treatment in DMARD- and steroid naÃve early rheumatoid arthritis patients. The danish cimestra-study. Annals of the Rheumatic Diseases, 2013, 71, 655.12-655.	0.9	0
85	FRI0017â€Ox40 and ox40l are highly associated with autoantibody formation in early rheumatoid arthritis, and predict flare after anti-tnf discontinuation Annals of the Rheumatic Diseases, 2013, 72, A374.1-A374.	0.9	1
86	OP0223â€M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD naÃ⁻ve rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 131.1-131.	0.9	1
87	Goal-setting in multidisciplinary team care for patients with rheumatoid arthritis: An international multi-center evaluation of the contents using the International Classification of Functioning, Disability and Health as a reference. Journal of Rehabilitation Medicine, 2013, 45, 888-899.	1.1	21
88	What's in the black box of arthritis rehabilitation? A comparison of rehabilitation practice for patients with inflammatory arthritis in Northern Europe. Journal of Rehabilitation Medicine, 2013, 45, 458-466.	1.1	13
89	SAT0391â€Does dynamic contrast-enhanced mri provide better separation of active early rheumatoid arthritis patients and healthy controls than conventional MRI?:. Annals of the Rheumatic Diseases, 2013, 71, 604.2-605.	0.9	O
90	SAT0597â€Course and Outcome of Rehabilitation Care in Different Rheumatological Diagnosis Groups. A Descriptive Study using the Star-Etic Registry Annals of the Rheumatic Diseases, 2013, 72, A784.3-A785.	0.9	0

#	Article	IF	Citations
91	Dynamic gadolinium-enhanced magnetic resonance imaging allows accurate assessment of the synovial inflammatory activity in rheumatoid arthritis knee joints: a comparison with synovial histology. Scandinavian Journal of Rheumatology, 2012, 41, 89-94.	1.1	61
92	Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Annals of the Rheumatic Diseases, 2012, 71, 851-856.	0.9	70
93	Correlation between computer-aided dynamic gadolinium-enhanced MRI assessment of inflammation and semi-quantitative synovitis and bone marrow oedema scores of the wrist in patients with rheumatoid arthritisa cohort study. Rheumatology, 2012, 51, 134-143.	1.9	47
94	The impact on self-efficacy of different types of follow-up care and disease status in patients with rheumatoid arthritis—A randomized trial. Patient Education and Counseling, 2012, 88, 121-128.	2.2	43
95	Development of a framework identifying domains and elements of importance for arthritis rehabilitation. Journal of Rehabilitation Medicine, 2012, 44, 406-413.	1.1	20
96	It Means Everything: Continuing Normality of Everyday Life for People with Rheumatoid Arthritis in Early Remission. Musculoskeletal Care, 2012, 10, 162-170.	1.4	28
97	Everyday Life with Rheumatoid Arthritis and Implications for Patient Education and Clinical Practice: A Focus Group Study. Musculoskeletal Care, 2012, 10, 29-38.	1.4	76
98	Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naA¬ve rheumatoid arthritis patients is up-regulated and not influenced by 1Âyear of clinically effective treatment. Rheumatology International, 2012, 32, 501-504.	3.0	8
99	Diurnal variation of connective tissue metabolites in early and long-standing rheumatoid arthritis and in healthy individuals. Scandinavian Journal of Rheumatology, 2011, 40, 88-94.	1.1	6
100	Being an outpatient with rheumatoid arthritis – a focus group study on patients' selfâ€efficacy and experiences from participation in a short course and one of three different outpatient settings. Scandinavian Journal of Caring Sciences, 2011, 25, 394-403.	2.1	35
101	Circadian rhythm and the influence of physical activity on circulating surfactant protein D in early and long-standing rheumatoid arthritis. Rheumatology International, 2011, 31, 1617-1623.	3.0	10
102	Selfâ€Efficacy as an Outcome Measure and its Association with Physical Diseaseâ€Related Variables in Persons with Rheumatoid Arthritis: A Literature Review. Musculoskeletal Care, 2011, 9, 125-140.	1.4	22
103	Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. Arthritis and Rheumatism, 2011, 63, 2192-2202.	6.7	90
104	Cartilage Oligomeric Matrix Protein Associates Differentially with Erosions and Synovitis and Has a Different Temporal Course in Cyclic Citrullinated Peptide Antibody (Anti-CCP)-positive versus Anti-CCP-negative Early Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 1563-1568.	2.0	14
105	Synovitis and Osteitis Are Very Frequent in Rheumatoid Arthritis Clinical Remission: Results from an MRI Study of 294 Patients in Clinical Remission or Low Disease Activity State. Journal of Rheumatology, 2011, 38, 2039-2044.	2.0	101
106	Patterns of Magnetic Resonance Imaging Bone Erosion in Rheumatoid Arthritis â€" Which Bones Are Most Frequently Involved and Show the Most Change?: Figure 1 Journal of Rheumatology, 2011, 38, 2014-2017.	2.0	15
107	Prevalence of Rheumatoid Arthritis in the Southern Part of Denmark. Open Rheumatology Journal, 2011, 5, 91-97.	0.2	16
108	Selfâ€efficacy in rheumatoid arthritis: translation and test of validity, reliability and sensitivity of the Danish version of the Rheumatoid Arthritis Selfâ€Efficacy Questionnaire (RASE). Musculoskeletal Care, 2010, 8, 123-135.	1.4	19

#	Article	IF	CITATIONS
109	Uncoupling of Collagen II Metabolism in Newly Diagnosed, Untreated Rheumatoid Arthritis Is Linked to Inflammation and Antibodies Against Cyclic Citrullinated Peptides. Journal of Rheumatology, 2010, 37, 1113-1120.	2.0	13
110	Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Annals of the Rheumatic Diseases, 2010, 69, 1789-1795.	0.9	168
111	Does Clinical Remission Lead to Normalization of EQ-5D in Patients with Rheumatoid Arthritis and Is Selection of Remission Criteria Important?. Journal of Rheumatology, 2010, 37, 285-290.	2.0	42
112	Circadian pattern and the effect of standardized physical exercise on procollagen IIA N-peptide (PIIANP) in rheumatoid arthritis at different stages and in healthy individuals. Biomarkers, 2010, 15, 80-85.	1.9	4
113	Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year. Annals of the Rheumatic Diseases, 2010, 69, 1097.2-1102.	0.9	71
114	Increased Interleukin 21 (IL-21) and IL-23 Are Associated with Increased Disease Activity and with Radiographic Status in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology, 2010, 37, 2014-2020.	2.0	94
115	Circulating surfactant protein -D is low and correlates negatively with systemic inflammation in early, untreated rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R39.	3.5	19
116	Plasma Adiponectin in Patients with Active, Early, and Chronic Rheumatoid Arthritis Who Are Steroid- and Disease-Modifying Antirheumatic Drug-Naive Compared with Patients with Osteoarthritis and Controls. Journal of Rheumatology, 2009, 36, 1885-1891.	2.0	106
117	MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Annals of the Rheumatic Diseases, 2009, 68, 384-390.	0.9	335
118	What Factors Influence the Health Status of Patients with Rheumatoid Arthritis Measured by the SF-12v2 Health Survey and the Health Assessment Questionnaire?. Journal of Rheumatology, 2009, 36, 2183-2189.	2.0	39
119	Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatology International, 2009, 29, 411-415.	3.0	59
120	Mannose-Binding Lectin Gene Polymorphisms Are Associated with Disease Activity and Physical Disability in Untreated, Anti-Cyclic Citrullinated Peptide-Positive Patients with Early Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 731-735.	2.0	19
121	Remission and rheumatoid arthritis: Data on patients receiving usual care in twentyâ€four countries. Arthritis and Rheumatism, 2008, 58, 2642-2651.	6.7	156
122	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Research and Therapy, 2008, 10, R30.	3.5	387
123	Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers, 2008, 13, 59-78.	1.9	80
124	Magnetic resonance imaging and bone scintigraphy in the differential diagnosis of unclassified arthritis. Annals of the Rheumatic Diseases, 2008, 67, 48-51.	0.9	52
125	Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Annals of the Rheumatic Diseases, 2008, 67, 815-822.	0.9	93
126	Incidence of Rheumatoid Arthritis in the Southern part of Denmark from 1995 to 2001. Open Rheumatology Journal, 2007, 1, 18-23.	0.2	46

#	Article	IF	Citations
127	Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis and Rheumatism, 2006, 54, 1401-1409.	6.7	160
128	Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study. Annals of the Rheumatic Diseases, 2006, 65, 1208-1212.	0.9	58
129	Fibroblastic rheumatism: a Scandinavian case report. Annals of the Rheumatic Diseases, 2005, 64, 156-157.	0.9	16
130	Can magnetic resonance imaging differentiate undifferentiated arthritis?. Arthritis Research and Therapy, 2005, 7, 243.	3.5	8
131	Low field dedicated magnetic resonance imaging in untreated rheumatoid arthritis of recent onset. Annals of the Rheumatic Diseases, 2001, 60, 770-776.	0.9	82
132	Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. British Journal of Rheumatology, 1999, 38, 618-626.	2.3	156
133	Bone Metabolism in Patients with Systemic Lupus Erythematosus: Effect of disease activity and glucocorticoid treatment. Scandinavian Journal of Rheumatology, 1998, 27, 197-206.	1.1	41
134	Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone, 1996, 19, 157-163.	2.9	63
135	Serum aminoterminal propeptide of type III procollagen after cardiac transplantation and the effect of rejection. American Journal of Cardiology, 1996, 78, 1406-1410.	1.6	9
136	Intra-articular and circulating levels of type I and III collagen markers in inflammatory and degenerative joint disease. Acta Orthopaedica, 1995, 66, 147-148.	1.4	0
137	Dose-Response Study of Human Growth Hormone in Venous Ulcers: Influence on Healing and Synthesis of Collagen Types I and III. Phlebology, 1994, 9, 92-98.	1.2	1
138	Collagen metabolism during wound healing in rats. The aminoterminal propeptide of type III procollagen in serum and wound fluid in relation to formation of granulation tissue. Apmis, 1993, 101, 557-564.	2.0	13
139	Serum Levels of Aminoterminal Type III Procollagen Peptide and Hyaluronan Predict Mortality in Systemic Sclerosis. Scandinavian Journal of Rheumatology, 1992, 21, 5-9.	1.1	37
140	Collagen Types I and III Propeptides as Markers of Healing in Chronic Leg Ulcers A Noninvasive Method for the Determination of Procollagen Propeptides in Wound Fluidâ€"Influence of Growth Hormone. Annals of Surgery, 1992, 216, 684-691.	4.2	26
141	Hepatic extraction of the aminoterminal propeptide of type III procollagen before and after bile duct ligation in pigs. Liver, 1991, 11, 310-315.	0.1	2
142	Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: Relation to disease activity and effect of chemotherapy. American Journal of Hematology, 1990, 33, 18-26.	4.1	29
143	Splanchnic and renal extraction of circulating type III procollagen aminoterminal propeptide in patients with normal liver function and in patients with alcoholic cirrhosis. Hepatology, $1990, 11, 957-963$.	7.3	25
144	Different Effects of Thyroid Disease on Serum Levels of Procollagen III <i>N</i> -Pep tide and Hyaluronic Acid. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 1016-1021.	3.6	16

#	Article	IF	CITATIONS
145	Hepatic and renal extraction of circulating type III procollagen amino-terminal propeptide and hyaluronan in pig. Journal of Hepatology, 1989, 9, 177-183.	3.7	38
146	Serum aminoterminal type III procollagen peptide. Apmis, 1988, 96, 793-804.	2.0	36
147	Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders. Clinical Rheumatology, 1988, 7, 61-68.	2.2	11
148	The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis. Rheumatology International, 1988, 8, 1-9.	3.0	24
149	Collagen type IV and procollagen type III during granulation tissue formation: a serological, biochemical, immunohistochemical and morphometrical study on the viscose cellulose sponge rat model. European Journal of Clinical Investigation, 1988, 18, 352-359.	3.4	23
150	Is the aminoterminal propeptide of type III procollagen degraded in the liver?. Journal of Hepatology, 1988, 6, 144-150.	3.7	27
151	Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine Annals of the Rheumatic Diseases, 1988, 47, 116-126.	0.9	58
152	Connective tissue metabolites in serum as markers of disease activity in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 1988, 6, 129-34.	0.8	9
153	Serum aminoterminal type III procollagen peptide. Relation to biosynthesis of collagen type III in experimentally induced granulation tissue in rats. Apmis, 1988, 96, 793-804.	2.0	11
154	Serum and urinary aminoterminal type III procollagen peptide in progressive systemic sclerosis: relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites. Journal of Rheumatology, 1988, 15, 460-7.	2.0	25
155	Serum aminoterminal procollagen type III peptide in acute viral hepatitis. A longâ€term followâ€up study. Liver, 1987, 7, 96-105.	0.1	22
156	Serum aminoterminal type III procollagen peptide and the 7S domain of type IV collagen in patients with alcohol abuse Relation to ultrastructural fibrosis in the acinar zone 3 and to serum hyaluronan. Liver, 1987, 7, 339-346.	0.1	54
157	Serum amino-terminal type III procollagen peptide in rheumatoid arthritis. Relationship to disease activity, treatment, and development of joint erosions. Arthritis and Rheumatism, 1986, 29, 592-599.	6.7	66
158	Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis. Clinical and Experimental Rheumatology, 0, , .	0.8	4